Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 14/20 | 1.00 |
| ▸ | DBF4 | Q9UBU7 | 14/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049004 | 0.87 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL5733147 | 0.87 | CDC7 (1.00) | CDC7DBF4TRPM8KDM4E | |
| SCHEMBL6338322 | 0.87 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15049060 | 0.85 | TRPM8 (0.80) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15049096 | 0.85 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15048955 | 0.85 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL11121421 | 0.85 | CDC7 (0.76) | CDC7DBF4TRPM8 | |
| SCHEMBL5239544 | 0.84 | CDC7 (0.85) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL8324969 | 0.84 | CDC7 (1.00) | CDC7DBF4TRPM8 | |
| SCHEMBL27997098 | 0.84 | TRPM8 (0.78) | CDC7DBF4TRPM8MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | claimed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | claimed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | claimed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | claimed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | claimed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | claimed |
| CN-104220069-B | Trpm8 antagonists | 多姆皮制药公司 | 2018-10-02 | — | — | CN | disclosed |
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0858444-A4 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0858444-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5750549-A | ANTIINFLAMMATORY AGENTS OR ANALGESICS | MERCK & CO., INC. (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997014671-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-4528291-A | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility | SCHERING CORPORATION (US) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | CDC7 2527/4885DBF4 3635/4885TRPM8 1/4885 |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPV1 | CDC7 3237/4885DBF4 3574/4885TRPM8 1/4885 |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | CDC7 893/4885DBF4 4312/4885TRPM8 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.